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Abstract 
Introduction: Chlordimeform, just as other formamidine pesticides, induces permanent region- and sex-dependent on monoam-
inergic neurotransmitter systems’ development, effects that may be related to monoamine oxidase (MAO) inhibition. Nevertheless, 
chlordimeform is a very weak MAO inhibitor, which suggests other mechanisms’ implication. In this regard, as chlordimeform alters 
testosterone and estradiol levels in frontal cortex and stratium, which may dysregulate the enzymes’ expression that mediates the 
synthesis and metabolism of monoaminergic neurotransmitters systems. Thus, an alteration of these hormones and enzymes in 
other altered brain regions could also mediate the observed effects.
Objectives and methods: For the purpose of confirming that formamidines produce permanent alterations of monoamine neuro-
transmitters’ systems through the disruption of sex hormones in the hipoccampus, by alteration of the expression of the enzymes 
that synthesize and or metabolize these neurotransmitters, hippocampus’ testosterone and estradiol levels at 11 days of age, as 
well as the expression of MAO, COMT, BDH, TH, TRH and AD enzymes at 60 days of age after maternal exposure to chlordimeform 
(5mg/kg body weight) were evaluated.
Results: Our results show an important decrease in testosterone levels, in addition to a significant decrease in estradiol levels in 
hippocampus of rats at 11 days of age. We also observed sex interaction with treatment in the content of T and E2, and we deter-
mined a bigger increase in the expression of COMT in females than in males. Chlordimeform treatment did not alter the expression 
of MAO and BDH enzymes, yet decreased the expression of the TH enzyme and increased the COMT, BDH, TH and TRH enzymes 
in both sexes.
Conclusions: The present findings indicate that after maternal exposure to formamidines, in general, and chlordimeform, in particu-
lar, the previously mentioned compound induces a permanent alteration of monoaminergic neurotransmitters, by the alteration of 
the enzymes that synthetize these neurotransmitters, which is successively mediated by sex hormones disruption, in hippocampus.
Keywords: Chlordimeform; formamidines; neurodevelopmental toxicity; COMT; BDH; TH; TRH; rats; human risk assessment 
Resumen
Introducción: El clordimeformo, al igual que otros plaguicidas formamidínicos, induce alteraciones permanentes de los sistemas 
de neurotransmisores monoaminérgicos región- y sexo-dependientes. Es posible que la inhibición de la enzima monoamino oxi-
dasa (MAO) pueda mediar estos efectos, pero la inhibición tan leve sufrida por la MAO en presencia de este compuesto sugiere 
la existencia de otros mecanismos implicados. En este sentido, se ha descrito una alteración en los niveles de testosterona y 
estradiol en el cuerpo estriado y en la corteza frontal en presencia de clordimeformo, que puede dar lugar a una alteración de la 
expresión de las enzimas que sintetizan y metabolizan dichos neurotransmisores. Así, una alteración en estas hormonas y enzimas 
en las otras regiones afectadas también podría mediar los efectos observados en las mismas.
Objetivos y métodos: Con el objetivo de confirmar que las formamidinas causan alteraciones permanentes de los neurotransmi-
sores monoaminérgicos mediante la disrupción de las hormonas sexuales en el hipocampo debido a la alteración de la expresión 
de las enzimas responsables de sintetizarlos y/o metabolizarlos, se evaluaron los efectos en el hipocampo de ratas macho y hembra 
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Introduction 
Formamidine pesticides as amitraz have been described 
to produce permanent alterations on central nervous sys-
tem’s (CNS) development, like those that affect mono-
amine neurotransmitter systems1. Chlordimeform [N2-(4-
chloro-o-tolyl)-N1.N1-dimethylformamidine] (Figure 1), 
which belongs to formamidine’s family too, has also been 
reported to induce permanent alterations of serotoniner-
gic, noradrenergic and dopaminergic systems in a region 
–and a sex– dependent way2,3. 
However, the implied mechanisms in these effects are 
still not clear. Monoaminergic neurotransmitters play a 
role during development, defined as “morphogenetic”4-7 
and changes in catecholamine levels’ during brain de-
velopment may induce both structural and functional 
alterations8. As formamidines have been reported to in-
hibit monoamine oxidase (MAO)9-10, which participates in 
metabolic inactivation of the neurotransmitters serotonin 
(5-HT), norepinephrine (NE), and dopamine (DA), these 
effects may mediate the observed alterations on mono-
aminergic neurotransmitters. However, chlordimeform is 
a very weak MAO inhibitor, which could mean that other 
mechanisms are involved.
Conversely, formamidines are endocrine disruptors and 
particularly, chlordimeform and amitraz have been report-
ed to alter serum hormone levels19,20. The observed al-
terations in NE, DA and 5-HT and its metabolites levels’ 
observed in rats’ brain after formamidines exposure may 
be caused by a possible change on those sex steroid 
hormones that modulate the expression of enzymes 
such as tyrosine hydroxylase (TH), dopamine-β-hydrox-
ylase (DBH), tryptophan hydroxylase (TRH), MAO, cat-
echol-O-metyltransferase (COMT), aldehyde dehydroge-
nase (AD), aldehyde reductase (AR) which are necessary 
for the synthesis and metabolism of these neurotrans-
mitters11-18. To this effect, after prenatal and postnatal 
exposure to chlordimeform, we observed a disruption 
in testosterone and estradiol levels in frontal cortex and 
striatum, which may be responsible of changes in the 
expression of TH and TRH20,21. In this way, these mech-
anisms could explain chlordimeform’s, as well as other 
formamidine pesticides’ effects observed on monoamin-
ergic neurotransmitters systems.
Therefore, we performed a study to determine if maternal 
exposure to chlordimeform during gestation and lactation 
induces permanent alterations on the enzymes that pro-
duce and metabolize 5-HT, NE and DA neurotransmitters 
in hippocampus at adult age, through sex hormones dis-
ruption, which could explain the effect observed on these 
neurotransmitters in a sex –and region– dependent way. 
Chlordimeform was chosen because it is the most repre-
sentative compound of formamimidines family, all of which 
are weak MAO inhibitors. This allows us a clearer study 
whether the permanent changes observed on levels of 
these neurotransmitters are caused by an alteration of the 
enzymes that catalyse the synthesis and metabolism of 
these neurotransmitters rather than to MAO inhibition.
Materials and methods 
Biological material 
All experiments were performed in accordance with Euro-
pean Union guidelines (2003/65/CE) and Spanish regu-
lations (BOE 67/8509-12, 1988) regarding the use of lab-
oratory animals. Eight pregnant Wistar rats were housed 
individually in polycarbonate cages and were assigned 
randomly to two experimental groups: a chlordimeform 
treatment group (n = 4) and a control group (n = 4).
sobre los niveles de testosterona y estradiol a los 11 días de edad. Aparte, también se evaluó la expresión de las enzimas MAO, 
COMT, BDH, TH, TRH, y AD a los 60 días de edad tras la exposición maternal al clordimeformo (5 mg/kg de peso corporal). 
Resultados: Nuestros resultados demuestran que el clordimeformo indujo, en el hipocampo de las ratas observadas a los 11 días 
de edad, una disminución significativa de los niveles de testosterona, así como un incremento reseñable de los niveles de estradiol. 
Por otro lado, se observó una interacción por sexo con el tratamiento en el contenido de T y E2 y se advirtió también una mayor ex-
presión de las enzimas COMT [58,83% (P<0,001)], AD [46,74% (P<0,001)], TH [43,65% (P<0,001)] y TRH [37,85% (P<0,001)] en las 
hembras que en los machos. El tratamiento con clordimeformo no causó alteración ninguna sobre la expresión de las enzimas MAO y 
BDH, pero indujo una disminución en la expresión de la enzima TH y un aumento en la expresión de las enzimas COMT, BDH, y TRH 
tanto en machos como en hembras. 
Conclusiones: Los presentes resultados indican que las formamidinas, en general, y particularmente el clordimeformo, inducen 
una alteración permanente de los sistemas de neurotransmisores monoaminérgicos en el cuerpo estriado tras la exposición ma-
ternal, mediante la alteración de las enzimas que metabolizan y sintetizan estos neurotransmisores, que es causada a su vez por 
la alteración de las hormonas sexuales.
Palabras clave: Clordimeformo; formamidinas; neurotoxicidad en el desarrollo; testosterona; estradiol; COMT; BDH; TH; TRH; 
ratas; evaluación del riesgo para el hombre
Figure 1: Chlodimeform chemical structure (C10H13Cl N2).
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Test Chemical and Treatment
Chlordimeform (Sigma, Madrid, Spain) was dissolved in 
corn oil to provide fast and complete absorption and was 
administered orally by gavage in a volume of 2 mg/ml. 
The animals received, daily, chlordimeform at the dose 
of 5 mg/kg on days 6 to 21 of pregnancy (GD 6-21) and 
on days 1 to 10 of lactation (PN 1-10). Control dams 
received vehicle (corn oil 2.5 ml/kg) on the same sched-
ules. Dose of chlordimeform was selected based on a 
previous preliminary study that indicated that this dose 
was the higher one that did not cause weight loss or 
mortality, reduction of food or water intake as well as did 
not induce haematological modifications or other clinical 
histopathological signs of overt toxicity. None of the pre-
natal or postnatal treatment evoked a significant change 
in weight of hippocampus on PN 60 (data not shown).
Dams were examined daily throughout the gestation and 
lactation periods for mortality, general appearance and 
behaviour. The maternal body weights were measured 
on GD 1, GD 5, GD 6, GD 15 and GD 20. Food and wa-
ter consumption during pregnancy, length of gestation, 
litter size and sex ratio were also assessed. 
On PN1, all litters were examined externally, sexed and 
weighed. Litters were organized in groups of twenty-four 
pups, twelve males and twelve females. Litters were 
weighed at PN 1, PN 7, PN14 and PN 21. The offspring 
were weaned on lactation day 21 and were maintained 
in appropriate conditions, housed individually and with-
out any treatment with full access to food and water until 
adult age. The study was organized in treated groups of 
six males and six females randomly selected respective-
ly from the dams’ litters exposed to chlordimeform, and 
control groups of six males and six female’s pups ran-
domly selected respectively from the control dams’ litters.
At PN11, for the analysis of brain’s testosterone and es-
tradiol levels and at PN 60, for the analysis of MAO A, 
MAO B, COMT, BDH, AD, TH and TRH gene expression, 
male and female rats from control and treated groups 
(pups from control dams, and pups from dams exposed 
to chlordimeform, respectively) were sacrificed by de-
capitation. The brain was removed quickly and the hip-
pocampus was a rapidly dissected out at 4ºC22, since 
this brain region was previously describe to present sex 
differences in the effect observed on these neurotrans-
mitters systems and to be one of the most affected2,3. 
Tissues were rapidly weighed and stored at -80ºC until 
analysis. All data were collected by experimenters blind 
to the treatment condition of the offspring.
Estradiol and testosterone quantification
Estradiol and testosterone content were measured in 
hippocampus from treated animals in order to deter-
mine whether sex hormones are altered by chlordime-
form exposure. Estradiol and testosterone content in the 
hippocampus was measured using an enzyme immuno-
assay kit (Estradiol EIA Kit, Cayman Chemical Company, 
MI, USA), according to the manufacturer’s instruction. 
Tissues were homogenized in 300 μl of an equal mixture 
of ethyl acetate and 0.1 M phosphate-buffered saline. 
The homogenates were centrifuged at 21,000 g for 15 
min at 4ºC. The resulting mixture was then incubated in 
a MeOH/dry ice bath to solidify the aqueous phase (bot-
tom) and the organic phase was eluted into a new tube. 
The ethyl acetate portion was collected and dried. The 
dried material was reconstituted in 120 μl EIA buffer, and 
100 μl of the sample was used for EIA at duplicate. ELI-
SA values were obtained (pg/ml) and corrected for weigh 
tissue (mg/ml), producing a final unit of pg/mg and pre-
sented as a percentage of the untreated control.
Real-time PCR analysis
The MAOA, MAOB, COMT, AD, TH, TRH and DBH ex-
pression was measured in hippocampus tissue from 
control and chlordimeform treated animals in order to de-
termine whether chlordimeform, through sex hormones 
disruption, alters permanently the expression of these en-
zymes. Total RNA was extracted using the Trizol Reagent 
method (Invitrogen, Madrid, Spain). The final RNA con-
centration was determined using a Nanodrop 2000 spec-
trophotometer (Thermo Fisher Scientific, Madrid, Spain), 
and the quality of total RNA samples was assessed using 
an Experion LabChip (Bio-Rad, Madrid, Spain) gel. First-
strand cDNA was synthesized with 1000 ng of cRNA by 
using a PCR array first strand-synthesis kit (C-02; Super-
Array Bioscience, Madrid, Spain) in accordance with the 
manufacturer’s instructions and including a genomic DNA 
elimination step and external RNA controls. After reverse 
transcription, QPCR was carried out using prevalidat-
ed primer sets (SuperArray Bioscience) for mRNAs en-
coding MAOA (PPR46359A), COMT (PPR06789A), AD 
(PPPR43520B), TH (PPR45220F), TRH (PPR48244A), 
DBH (PPR52652A), and ACTB (PPM02945B). ACTB was 
used as an internal control for normalization. Reactions 
were run on a CFX96 using Real-Time SYBR Green PCR 
master mix PA-012 (SuperArray Bioscience). The thermo-
cycler parameters were 95°C for 10 minutes, followed by 
40 cycles of 95°C for 15 seconds and 72°C for 30 sec-
onds. Relative changes in gene expression were calculat-
ed using the Ct (cycle threshold) method. The expression 
data are presented as actual change multiples23. 
Data analysis
Statistical analysis of data was performed using a Stat-
graphics software, version Plus 4.1 for windows. Values 
are expressed as mean ± S.E.M. obtained from 12 an-
imals, six males and six females, in each group (con-
trol and treated groups). For values combined for males 
and females, a two-way ANOVA with treatment × sex 
interaction was the initial test used. Where a significant 
treatment × sex interaction was detected, a separate 
Student’s t test was carried out for each sex. The re-
sults were considered significant at P<0.05. Results 
significantly different from controls are also presented as 
change from control (%).
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Results 
Maternal and offspring body weight, physical and general 
activity development were unaffected by the exposure of 
dams to chlordimeform (5 mg/kg bw orally on days 6 to 
21 of pregnancy and 1 to 10 of lactation).
Estradiol and testosterone quantification
Oral treatment with chlordimeform to dams during the 
gestation period from day 6 to day 21 and during lacta-
tion from day 1 to day 10 affected the content of T and 
E2 in the hippocampus region of offspring rats at the age 
of 11 days. The content of T (ng/g tissue) in the region 
of hippocampus in the control group and treated group 
is presented in table I. The content of E2 (ng/g tissue) in 
the region of the hippocampus of the control group and 
the treated group is presented in table II. The results 
expressed in tables I and II show that in 11 days old rats 
treated during gestation days 6-21 and during lactation 
days 1-10 through their mothers, a statistically significant 
loss of T content and a significant increase in E2 content 
in the hippocampus compared to control animals was 
produced. A sex interaction with treatment in the con-
tent of T and E2 was observed (Figure 2). In hippocam-
pus, the increase observed of E2 content was 39,08% 
(P<0,001) and 68,13% (P<0,001) in males and females, 
respectively, and the loss in the content of T was 16,97% 
(P<0,001) and  22,97% (P<0,001) in males and females, 
respectively (Figure 2).
 
Real-time PCR analysis
Oral treatment with chlordimeform to dams during the ges-
tation period from day 6 to day 21 and during lactation 
from day 1 to day 10 affected the COMT, AD, TH and TRH 
gene expression of offspring rats at the age of 60 days. In 
60 days old rats treated during gestation days 6-21 and 
during lactation days 1 to 10 an increase in the expression 
of COMT [67,39% (P<0,001) and 45,71% (P<0,001)], 
AD [24,62% (P<0,01) and 39,54% (P<0,001)] and TRH 
[52,72% (P<0,001) and 26,75% (P<0,01)] enzymes and a 
decrease in TH [63,45% (P<0,001) and 26,35% (P<0,01)] 
enzyme in males and females, respectively, in hippocam-
pus with respect to control animals was observed. No ef-
fect on gene expression of MAO, and BDH enzymes was 
observed (Figure 3). A sex difference in COMT, AD, TH 
and TRH gene expression was observed, being higher the 
expression of COMT [58,83% (P<0,001)], AD [46,74% 
(P<0,001)], TH [43,65% (P<0,001)] and TRH [37,85% 
(P<0,001)] enzymes in female than in male rats (Figure 4). 
Table I: Tissue T (pg/ml) content determined in striatum from male and female rats at 11 days of age treated with vehicle or chlordimeform (5 mg/kg bw orally on days 
6 to 21 of pregnancy and 1 to 10 of lactation). 
Values are mean ± S.E.M.; control animals (n= 6 males, n= 6 females); treated group (n= 6 males, n= 6 females).
Statistical significance is reported for the ***P<0.001 levels compared with the control group.
Hippocampus
 Animal Control group Treated group Control group Treated group
  Males Males Females Females
 1 301,43 253,57 305,87 232,65
 2 296,87 256,18 298,76 231,67
 3 309,65 254,84 296,16 226,86
 4 295,96 248,76 302,87 229,76
 5 310,65 247,87 294,76 228,87
 6 304,74 249,36 301,76 236,81
 Mean ± 303,22±2,55*** 251,76±1,44*** 300,03±1,73*** 231,10±1,41***
 SEM  (-16,97%)  (-22,97)
Table II: Tissue E2 (pg/ml) content determined in striatum from male and female rats at 11 days of age treated with vehicle or chlordimeform (5 mg/kg bw orally on 
days 6 to 21 of pregnancy and 1 to 10 of lactation).  
Values are mean ± S.E.M.; control animals (n= 6 males, n= 6 females); treated group (n= 6 males, n= 6 females).
Statistical significance is reported for the ***P<0.001 levels compared with the control group.
Frontal Cortex
 Animal Control group Treated group Control group Treated group
  Males Males Females Females
 1 83,40 132,34 75,67 124,76
 2 93,43 125,45 83,31 128,74
 3 101,34 136,26 77,51 135,82
 4 92,61 129,71 81,75 132,87
 5 103,41 132,45 73,93 137,75
 6 96,45 137,43 78,54 131,78
 Mean ± 95,10±2,92*** 132,27±1,79*** 78,45±1,46*** 131,9±1,93***
 SEM  (39,08%)  (68,13%)
35Medicina Balear 2017; 32 (3); 31-39 
Hippocampal alteration of monoaminergic neurotransmitters biosynthesis and metabolism in CNS in rats, 
after prenatal and postnatal exposure to chlordimeform, through sex hormones disruption
Discussion 
Chemical exposure of dams during pregnancy or lacta-
tion could induce developmental neurotoxic effects that 
include alterations in behaviour, neurohistology, neuro-
chemistry and/or gross dysmorphology of CNS, which 
are manifest in the adulthood. Previous studies described 
that formamidines induce permanent alteration in de-
veloping monoamine neurotransmitter systems in a sex 
–and region– dependent way1-3. Specifically, chlordime-
form has been reported to induce an alteration of 5-HT, 
DA and NE neurotransmitters and their metabolites in a 
sex-dependent way in only the regions of frontal cortex, 
striatum and hippocampus2,3. The mechanism by which 
these permanent effects on monoaminergic systems take 
place is not completely understood, but monoamine neu-
rotransmitters regulate brain development prior to assum-
ing their roles as transmitters in the mature brain24-26, thus 
any circumstance that affects these neurotransmitters in 
the developing brain can alter the final structure and func-
tion of that brain. Since the endogenous levels of 5-HT, 
DA and NE are highly regulated by MAO, any change in 
this enzyme can profoundly affect the developing brain. 
In this regard, it has been reported that gestational ex-
posure to MAO inhibitors clorgyline and deprenyl pro-
duces in offspring at 30 days of age, a significant reduc-
tion of serotonergic innervation particularly in the frontal 
cortex27, but not in the dopaminergic and noradrenergic 
innervation, which suggests that besides MAO inhibition 
other mechanism should be implicated in the alteration 
observed. However, chlordimeform is a very weak MAO 
inhibitor28-30, but presents similar permanent regional and 
sexual dependent effects than amitraz, which is a potent 
MAO inhibitor9. These data suggest that MAO inhibition 
could not produce the alterations in monoaminergic neu-
rotransmitters systems observed, confirming that other 
mechanisms are involved. 
Otherwise, steroids play a role in the development of cat-
echolamine systems31-34, and play a critical role in mam-
malian brain developmental of both genders35. The pres-
ent study shows that prenatal and postnatal exposure 
to chlordimeform (5 mg/kg bw orally on days 6 to 21 of 
pregnancy and 1 to 10 of lactation) was not able to in-
duce maternal toxicity, since during pregnancy maternal 
weight gain of treated rats was not modified. However, 
chlordimeform administered during pregnancy and lacta-
tion leads to a decrease in T levels and an increase in E2 
levels at PN11, which is the critical period of time when 
sexual differentiation takes place, in male and female rats’ 
brain. This treatment produced also a permanent reduc-
tion of the TH gene expression and a permanent induc-
tion of COMT, BDH and TRH gene expression, which 
catalyse the synthesis and metabolism of monoaminer-
gic neurotransmitters, at 60 days of age in male and fe-
male rats’ hippocampus. Previously, chlordimeform has 
Figure 2: Tissue T and E2 (pg/ml) content determined in striatum from male and female rats at 11 days of age treated with vehicle or chlordimeform (5 mg/kg bw orally 
on days 6 to 21 of pregnancy and 1 to 10 of lactation). 
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been reported to decrease T and E2 levels at PN11 in 
frontal cortex20 and striatum21 and to decrease TH and 
TRH gene expression in frontal cortex20 and COMT, BDH, 
TH y TRH in striatum21 at PN60, which support the effect 
observed. The sex and region differences in the enzymes 
altered in this region correspond with the alteration ob-
served on the monoaminergic neurotransmitters in this 
region, which could explain the effect observed.
Sex hormones’ effect on monoaminergic and indolamin-
ergic neurotransmitters in CNS includes synthesis, vesic-
ular and/or synaptic release and metabolism regulation37.
The sex hormones provenance in the brain, could be 
from gonads or from endogenous synthesis, as previ-
ously described, whose contribution to the final effect de-
pends on the region and sex steroid hormone37-40. Estra-
diol alters the levels of enzymes that synthesize DA, NE 
and 5HT, as well as those that degrade these neurotrans-
mitters12,14,16,41-42. E2 elevated mRNA levels of TH, the first 
and major rate limiting enzyme in catecholamine biosyn-
thesis42 and enhanced TRH mRNA expression12. In addi-
tion, T and DHT regulated the synthesis and metabolism 
of monoamines17. In this sense, T and DHT increased 
TH protein and COMT, MAO-A and MAO-B mRNAs15. In 
the same way, DHT decreased neurotransmitter turnover 
of DOPAC/DA, MHPG/NE, and 5-HIAA/5-HT of gona-
dectomized animals13. These previous data support that 
the disruption in sex hormones observed, mediate the 
effects observed on these enzymes after chlordimeform 
treatment, and so, on the monoaminergic neurotrans-
mitters. However, we cannot rule out that an alteration 
of monoaminergic neurotransmitters transporters, which 
have been shown to be regulated by estradiol43-46, might 
contribute to the effect observed.
Furthermore, other possible mechanisms that may contrib-
ute to the permanent alterations observed on monoamin-
ergic neurotransmitters systems could be a direct action of 
chlordimeform on neuronal cell replication, differentiation, 
axonogenesis and synaptogenesis and functional devel-
opment of neurotransmitter systems, effects that could re-
sult in behavioural alterations observed in previous studies 
after developmental exposure to chlordimeform47. The loss 
of dopaminergic, serotoninergic and noradrenergic projec-
tions could also play an important role in the behavioural 
and motor alterations. In this regard, hippocampus partic-
ipates in the regulation of learning and memory process-
es, among other actions48-51, thus, it could be considered 
that these processes could be compromised by exposure 
during gestation and lactation to formamidines. Moreover, 
Figure 3: Sex difference results from real-time PCR targeting MAO, COMT, BDH, AD, TH y TRH genes after chlordimeform treatment in male and female rats. MAO, 
COMT, BDH, AD, TH y TRH gene expression was compared to male rats results. Each bar represents mean ± SD of 6 samples. Levels were measured using QPCR. 
ACTB was used as an internal control. ***p ≤ 0.001, significantly different from males.
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Figure 4: Results from real-time PCR targeting MAO, COMT, BDH, AD, TH y TRH genes after chlordimeform treatment in male and female rats. MAO, COMT, BDH, 
AD, TH y TRH gene expression was compared to controls. Each bar represents mean ± SD of 6 samples. Levels were measured using QPCR. ACTB was used as an 
internal control. ***p ≤ 0.001, **p ≤ 0.01 significantly different from controls.
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neural functions like affect, anxiety, mood, fear and cog-
nitive function are modulated by estradiol, predominantly 
enhancing learning and memory, in addition to its well-doc-
umented role in reproduction51. Therefore, the neurotoxic 
effects observed by chlordimeform or amitraz exposure 
such as behavioral effects as hyperreactivity to external 
stimuli, aggressiveness, and motor incoordination, among 
others47,53, could be mediated by the alteration observed 
in these neurotransmitters. Neurofunctional disorders such 
as schizophrenia, aggressive behaviour, autism spectrum 
disorder and attention deficit hyperactivity disorder has 
been associated with imbalance in dopamine and other 
neurotransmitters in the developing brain54-59, so these al-
terations could also lead to development of some of these 
neurological disorders after formamidines exposure. Fur-
ther studies are needed to test whether these other mech-
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anisms described could be involved in the effects observed 
and to confirm that alteration of these neurotransmitter sys-
tems is the cause of some of these dysfunctions. 
DA, 5-HT and NE systems alterations observed after 
chlordimeform exposure in the frontal cortex and striatum 
were similar between them2,3, but not in the hippocam-
pus3. Moreover, the testosterone and estradiol hormone 
levels disruption produced after chlordimeform exposure 
in the frontal cortex striatum was also similar except in the 
hippocampus, as well as the effect on monoaminergic 
neurotransmitters regulating enzymes gene expression. 
These results suggests that the mechanisms through 
which monoaminergic neurotransmitters systems are 
altered in the brain regions affected after chlordimeform 
exposure is produced by the alteration in the expression 
of these enzymes, mediated through sex hormones dis-
ruption. The differences observed could be explained 
through the differences showed in the T and E2 disrup-
tion and in the expression of the enzymes that regulate 
the synthesis and metabolism of these neurotransmitters. 
In addition, the effects observed on DA, 5-HT and NE 
systems after amitraz exposures were also the same 
as those observed after chlordimeform exposure1, sug-
gesting that these mechanisms are the same in chlordi-
meform and amitraz in particular, and in formamidines in 
general. Further studies are needed to confirm whether 
this mechanism and others, probably involved in these 
effects, are the same in all brain regions studied and for 
all formamidines.
Conclusions 
To sumarize, our results suggest that the mechanism by 
which the alterations in the development of the mono-
aminergic neurotransmitter systems in hippocampus is 
mediated through disruption of estradiol and testoster-
one levels, which produced a permanent alteration of the 
expression of some of the enzymes that synthetize and 
metabolize these monoaminergic neurotransmitters. Fur-
ther studies are needed to check if other hormones are 
also involved in these effects and to determine whether 
they act directly on expression of the affected enzymes 
or inducting other genes that can regulate their expres-
sion. Otherwise, it should be determined whether there 
is a reduction in innervation in the regions affected that 
could also contribute to the effect observed. Moreover, 
it should be determined if all formamidines work in the 
same way and if these mechanisms are the same in all 
formamidines and in all of the brain regions affected by 
them. Due to the fact that monoaminergic neurotrans-
mitters dysfunctions are related with appetite, affective, 
neurological and psychiatric disorders, behavioral stud-
ies of formamidines are also needed to clarify the out-
comes of long-term alterations in these monoaminergic 
neurotransmitters systems. Right now, new formamidine 
molecules with therapeutic application are being devel-
oped. Until now, the risk assessment of the family of 
these compounds has been taken from the standpoint 
of carcinogenesis. Keeping in mind these results and 
our previous ones, it might be appropriate to reconsider 
the risk assessment of the members of this family based 
not only on their possible carcinogenic effects, but also 
in the neurotoxic effects during development mediat-
ed by endocrine disruption. The showed results are of 
great importance because they could lead to a better 
understanding of the mechanisms which are in charge 
of producing the neurotoxic alterations and should be 
incorporated into the risk assessment of pesticides for-
mamidines group. 
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